Holen Sie sich die Stockscreener-App
0.907
8.23%
0.069
Handel nachbörslich:
.92
0.013
+1.43%
Schlusskurs vom Vortag:
$0.838
Offen:
$0.8129
24-Stunden-Volumen:
138.18K
Relative Volume:
0.86
Marktkapitalisierung:
$51.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.52M
KGV:
-0.5096
EPS:
-1.78
Netto-Cashflow:
$-107.56M
1W Leistung:
+6.73%
1M Leistung:
+11.33%
6M Leistung:
-4.53%
1J Leistung:
-85.37%
1-Tages-Spanne:
$0.8129
$0.9174
1-Wochen-Bereich:
$0.75
$0.9174
52-Wochen-Spanne:
$0.6101
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Firmenname
Prelude Therapeutics Inc
Sektor
Branche
Telefon
(302) 467-1280
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Vergleichen Sie PRLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
0.907 | 46.69M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Eingeleitet | Jefferies | Buy |
| 2022-03-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-28 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2020-11-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
| 2020-10-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Tick level data insight on Prelude Therapeutics Incorporated volatilityMarket Movement Recap & Accurate Entry and Exit Point Alerts - Newser
Will Prelude Therapeutics Incorporated stock go up soon2025 Macro Impact & Weekly Momentum Stock Picks - Newser
Price momentum metrics for Prelude Therapeutics Incorporated explainedMarket Performance Report & Reliable Breakout Forecasts - Newser
Will Prelude Therapeutics Incorporated bounce back from current supportTrade Exit Summary & Weekly High Potential Alerts - Newser
Quantitative breakdown of Prelude Therapeutics Incorporated recent moveJuly 2025 Summary & Trade Opportunity Analysis Reports - Newser
How to build a dashboard for Prelude Therapeutics Incorporated stockPortfolio Update Summary & Stepwise Swing Trade Plans - Newser
What makes Prelude Therapeutics Incorporated stock price move sharplyEarnings Risk Report & Community Verified Swing Trade Signals - Newser
What recovery options are there for Prelude Therapeutics Incorporated [July 2025 Sentiment]High Yield Equity Trading Tips - Newser
Is Prelude Therapeutics Incorporated reversing from oversold territoryFree Value Investing Picks With Stability - Newser
Does Prelude Therapeutics Incorporated qualify in momentum factor screeningWatchlist Generator for Smart Money Signals - Newser
Prelude Therapeutics Incorporated stock trendline breakdownFree Trade Setups With Clear Risk Limits - Newser
Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionMarket Liquidity and Price Flow Analysis - Newser
Using data filters to optimize entry into Prelude Therapeutics IncorporatedAsset Safety Selection Using Quantitative Analysis - Newser
Published on: 2025-08-11 08:04:14 - Newser
Can Prelude Therapeutics (NASDAQ:PRLD) Afford To Invest In Growth? - Yahoo Finance
Prelude Therapeutics Incorporated’s volatility index tracking explainedMulti-Year Signal Summary and Entry Timing - Newser
Is it time to cut losses on Prelude Therapeutics IncorporatedMinimal Risk Growth Investment Opportunity Analysis - Newser
Can machine learning forecast Prelude Therapeutics Incorporated recoveryLong Term Stock Planner with Safety Checks - Newser
Prelude Therapeutics (PRLD) to Release Quarterly Earnings on Monday - Defense World
Published on: 2025-08-08 17:57:29 - Newser
Prelude Therapeutics Inc expected to post a loss of 44 cents a shareEarnings Preview - TradingView
Has Prelude Therapeutics Incorporated found a price floorLong-Term Investment Strategy Summary Guide - Newser
Using fundamentals and technicals on Prelude Therapeutics IncorporatedTrend Following Ideas with Volume Confirmation - Newser
What recovery options are there for Prelude Therapeutics IncorporatedFree Swing Trade Entry With Volume Triggers - Newser
Using data models to predict Prelude Therapeutics Incorporated stock movementFree ROI Boosting Trade Opportunity Calendar - Newser
Is Prelude Therapeutics Incorporated stock entering bullish territoryPre-Market Stock Movement Summary and Review - Newser
Published on: 2025-08-04 06:59:59 - Newser
What institutional investors are buying Prelude Therapeutics Incorporated stockFree Predictions - Jammu Links News
Published on: 2025-08-04 00:18:44 - Newser
Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):